According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Viridian Therapeutics, Inc. has reached an agreement with WuXi Biologics, which will manufacture and supply Viridian's investigational drug Veligrotug.

This collaboration marks a crucial step for Viridian in advancing the development and future commercialization of its core pipeline product, Veligrotug. By partnering with the global leading Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics, Viridian aims to ensure high-quality and scalable manufacturing capacity for its candidate drug.Veligrotug is a highly anticipated candidate therapy within Viridian’s pipeline. The implementation of this manufacturing supply agreement not only provides strong material support for subsequent clinical trials, but also paves the way for potential commercial launch. For biotech companies, securing manufacturing capacity with internationally recognized partners is an important strategic move to reduce R&D risks and accelerate product progression.The disclosure of this SEC filing communicates Viridian’s tangible progress in business operations to the market. Investors typically pay close attention to such collaborations involving the construction of core product supply chains, viewing them as key evidence for evaluating the company’s execution capabilities and future development potential.